The indication of Benlysta (belimumab) was extended after it significantly improved renal outcomes in those with active lupus nephritis.
List view / Grid view
systemic lupus erythematosus (SLE)
Data from the Phase I study of collaborative industry partnership AMP are now available, meaning scientists can benefit from access to important research about Rheumatoid Arthritis and Systemic Lupus Erythematosus.
The EU has approved a new subcutaneous formulation of Benlysta, as an add-on therapy in adult patients with active autoantibody-positive systemic lupus erythematosus...
8 June 2016 | By Victoria White, Digital Content Producer
Patients with SLE experienced a significantly greater response to treatment with Benlysta administered via subcutaneous injection compared to placebo...